Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
APGAR ScoreAssisted Delivery (FIGO)BPP (Manning Score)Bishop ScoreCARPREG II Cardiac RiskCervical Cancer StagingContraceptive Pearl IndexDoppler Matrix (UA/MCA)EFW (Hadlock)Endometrial StagingEndometrial ThicknessFGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey ScoreFetal Anemia (MCA PSV)GDM Diagnostic CriteriaGPA History IndicatorGail Model Breast RiskGestational Dating (LMP)HIV PMTCT ProtocolIOTA Simple RulesIVF Due Date & AMHIron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS ClassificationOvarian Cancer StagingPAS Hemorrhage RiskPPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS CriteriaSyphilis ManagementTORCH FrameworkVBAC Success ProbabilityVulvar Cancer StagingWeight Gain (IOM)mWHO Cardiac Risk
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

HIV PMTCT Protocol

HIV Management (PMTCT)

Prevention of Mother-to-Child Transmission

Standard of Care
  • Immediate initiation of Triple ART
  • Target VL: Undetectable at 36w
  • Infant Post-exposure Prophylaxis
  • Avoid prolonged ROM during labour
Mode of Delivery Criteria

Vaginal Delivery Safe

Viral Load < 50 copies/mL

Elective C-Section Indic.

Viral Load > 1000 copies/mL

Reference: WHO PMTCT Integrated Guidelines / CDC HIV Prevention Framework.

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Primary Clinical Uses

Guiding the mode of delivery (Vaginal vs Cesarean) in pregnant individuals living with HIV.
Determining the necessity for intrapartum intravenous Zidovudine (AZT).
Preventing Mother-to-Child Transmission (PMTCT) of HIV during labor and delivery.

Success Rate

With strict adherence to antiretroviral therapy (ART) and an undetectable viral load appropriately managed at delivery, the perinatal transmission rate of HIV drops from ~25% to less than 1%.

How it Works

Viral Load (VL) Thresholds near Delivery (34-36 wks)

VL < 50 copies/mL (Undetectable)Vaginal delivery indicated. IV AZT NOT required (though some protocols use cutoffs like >50 or >1,000 for AZT).
VL 50 – 999 copies/mLVaginal delivery generally supported. IV AZT IS recommended intrapartum.
VL ≥ 1,000 copies/mL (or unknown)Scheduled Cesarean delivery at 38 weeks. IV AZT IS required.

Clinical Pearls

Critical Intrapartum Rules

If viral load is strictly undetectable, avoiding artificial rupture of membranes (AROM), fetal scalp electrodes (FSE), and operative vaginal delivery is no longer absolutely mandated, but still strongly cautioned.
Avoid Methergine (methylergonovine) for postpartum hemorrhage routine prophylaxis if the patient is on a Protease Inhibitor (e.g., Ritonavir, Darunavir) or Cobicistat. Extreme vasoconstriction and catastrophic ischemia can occur due to CYP3A4 inhibition.

The Breastfeeding Shift (2023 Updates)

Historically, breastfeeding was an absolute contraindication for HIV-positive mothers in resource-rich settings. Modern DHHS guidelines now explicitly state that if a mother is virologically suppressed (undetectable) and strongly desires to breastfeed, providers should NOT contact Child Protective Services, but instead offer patient-centered, shared decision-making support.

Next Steps

Intrapartum Zidovudine (AZT) Dosing

01
Required if VL >1,000, 50-999, or unknown.
02
Loading Dose: 2 mg/kg IV over 1 hour.
03
Maintenance: 1 mg/kg/hour IV continuous infusion.
04
Target: Initiate 3 hours prior to scheduled C-section or immediately upon admission in labor.
05
Continue until umbilical cord clamping.

The Evidence

Primary Authority

Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission.

Department of Health and Human Services (DHHS). • NIH.. 2023;The absolute gold standard continuously-updating living document strictly governing all HIV management in pregnancy in the United States.

Origins & History

PACTG 076

The Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 published in 1994 was the revolutionary placebo-controlled trial that proved Zidovudine could prevent maternal-fetal transmission, fundamentally changing the trajectory of the global AIDS pandemic.

Last Comprehensive Review: 2026-07-17

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.